Table 2 The multivariate analysis of prognostic factors associated with PFS and OS

Age (years)

0.64 (0.1–19.71)

0.32 (0.01–199.21)

≤60

10/103

90.3 (87.4–96.0)

7/103

93.2 (88.3–98.1)

> 60

2/26

90.8 (84.5–97.1)

0/26

100 (NA)

Extranodal involvement

1.03 (0.36–2.98)

0.53 (0.11–2.65)

No

6/70

91.4 (84.7–98.1)

4/70

94.2 (91.4–97.1)

Yes

6/59

89.3 (81.3–97.3)

3/70

94.9 (92.1–97.8)

Ann Arbor Stage

2.81 (0.71–10.41)

3.87 (0.45–33.5)

I

2/56

96.0 (93.2–98.8)

1/56

98.1 (96.4–99.8)

II

10/73

86.3 (78.5–94.1)

6/73

91.8 (88.6–95.0)

ECOG PS

2.11 (0.36–6.23)

2.2 (0.49–9.93)

0

6/73

91.7 (85.4–97.9)

3/73

95.9 (93.6–98.2)

1

6/56

88.7 (80.1–97.3)

4/56

92.9 (89.5–96.3)

B symptoms

1.88 (0.36–9.69)

5.27 (0.81–34.3)

No

10/120

91.4 (86.3–96.5)

5/120

95.8 (94.1–97.6)

Present

2/9

77.8 (63.9–91.7)

2/9

77.8 (63.9–91.7)

LDH level

NA^a

NA^a

Normal

12/122

89.9 (84.4–96.4)

7/122

94.2 (92.1–96.3)

Elevated

0/7

100 (NA)

0/7

100 (NA)

IPI score

NA^a

NA^a

0–1

12/126

90.3 (85.1–95.6)

7/126

94.4 (92.4–96.4)

2

0/3

100 (NA)

0/3

100 (NA)

interim PET/CT

2.4 (0.66–9.03)

3.68 (0.71–19.12)

Negative

9/115

91.9 (86.8–97.1)

5/115

95.6 (93.7–97.5)

Positive

3/14

78.6 (67.6–89.6)

2/14

85.7 (76.3–95.1)